Patents Issued in June 12, 2018
-
Patent number: 9993404Abstract: Disclosed is a hair conditioning composition comprising: a cationic surfactant; a high melting point fatty compound having a melting point of 25° C. or higher; a material having a refractive index of from about 1.30 to about 1.70; and an aqueous carrier, wherein a composition has a transmittance of at least about 0.5%. The composition is further specified by either: (i) the material is a polyol having at least 3 hydroxyl groups and the polyol is contained at a level of above 30% to about 80% by weight of the composition; or (ii) the cationic surfactant is a salt of a mono-long alkyl amine and an acid. The compositions provides both translucent appearance and conditioning benefits, especially conditioning benefit on wet hair when used as a rinse-off conditioner and/or spreadability on hair.Type: GrantFiled: January 14, 2016Date of Patent: June 12, 2018Assignee: The Procter & Gamble CompanyInventors: Cedric Kofi Aurelien Callens, Tian Yong Lim, Toshiyuki Iwata
-
Patent number: 9993405Abstract: The present invention relates to a cosmetic or dermatological composition comprising, in a physiologically acceptable support: a) at least one merocyanine of formula (1) or (2). b) at least one oily phase comprising at least one amide compound of formula (I). The present invention also relates to a non-therapeutic cosmetic process for caring for and/or making up a keratin material, comprising the application, to the surface of the said keratin material, of at least one composition as defined above. The invention also relates to a non-therapeutic cosmetic process for limiting the darkening of the skin and/or improving the color and/or uniformity of the complexion, comprising the application, to the surface of the keratin material, of at least one composition as defined previously.Type: GrantFiled: January 20, 2014Date of Patent: June 12, 2018Assignee: L'OREALInventors: Angelina Roudot, Didier Candau, Xavier Marat, Alexandre Cavezza
-
Patent number: 9993406Abstract: Coloring agents for keratin fibers, in particular for human hair, include—based on their weight—at least one compound selected from the group of oxidation dye precursors, substantive dyes and mixtures thereof, 0.1 to 5% by weight dicarboxylic acid(s) having 2 to 10 carbon atoms and/or salt(s) of said acid(s), 20 to 95% by weight water and less than 0.1% by weight peroxide compound(s), result in oxidative coloring agents with improved fiber protection.Type: GrantFiled: January 19, 2017Date of Patent: June 12, 2018Assignee: Henkel AG & Co. KGaAInventors: Hartmut Manneck, Thomas Hippe, Stefan Hoepfner, Jessica Brender
-
Patent number: 9993407Abstract: Described herein are methods of cleaning a tooth comprising administering a composition comprising a zinc amino acid halide complex to the oral cavity; and retaining the composition in the oral cavity for a time sufficient to form a precipitate.Type: GrantFiled: January 20, 2017Date of Patent: June 12, 2018Assignee: Colgate-Palmolive CompanyInventors: Zhiqiang Liu, Long Pan, Shaotang Yuan, Jairajh Mattai, James G. Masters
-
Patent number: 9993408Abstract: The present invention provides compositions utilizing a first zwitterionic ammonio-alkanamide and/or zwitterionic ammonio-alkanoate surfactant according to Formula 1 and an ingredient selected from the group consisting a surfactant other than the first zwitterionic surfactant, emulsifiers, conditioning agents, emollients, moisturizers, humectants, thickeners, lubricants, chelating agents, fillers, binding agents, anti-oxidants, preservatives, active ingredients, fragrances, dyes, buffering agents, exfoliates, pH adjusters, inorganic salts, solvents, viscosity controlling agents and opacifying agents, wherein the composition is substantially free of alkylamidoamine and aminoalkylamine.Type: GrantFiled: September 17, 2015Date of Patent: June 12, 2018Assignee: Johnson & Johnson Consumer Inc.Inventors: Michael J. Fevola, Tobias J. Fuetterer, Neil Warren Boaz
-
Patent number: 9993409Abstract: The invention relates to a composition comprising: i) at least one oxidation base, preferably of heterocyclic and/or para-phenylenediamine type; and ii) at least one heteroaryl coupler of formula (I), with R1, R2, R3, A and X as defined in the description. The invention also relates to a process for dyeing keratin fibres using ingredients i) and ii); to a kit comprising ingredients i) and ii); and to the use of ingredient i) combined with ii) for dyeing keratin fibres. The composition of the invention leads to particularly powerful, chromatic and sparingly selective colourings.Type: GrantFiled: May 13, 2015Date of Patent: June 12, 2018Assignee: L'OREALInventors: Alain Lagrange, Boris Lalleman
-
Patent number: 9993410Abstract: A method for screening compounds and compositions that reduce cetyl pyridinium chloride activation of TRPA1 receptor or TRPV1 receptor.Type: GrantFiled: April 8, 2016Date of Patent: June 12, 2018Assignee: The Procter & Gamble CompanyInventors: John Christian Haught, Koti Tatachar Sreekrishna, Yakang Lin, Carrita Anne Hightower, Pierig Jean-Marie Lepont
-
Patent number: 9993411Abstract: The present invention relates to a composition for dyeing keratin fibres, comprising: at least one fatty substance, at least one surfactant; at least one oxidation base, at least one coupler of formula (B3) below and also salts thereof, optical and geometrical isomers and tautomers thereof, and hydrates thereof: (B3) in which; R1, R3, R5 represent a hydrogen; a C1-C8 alkyl or alkenyl, —SR or —OR; a (C1-C4)alkylcarbonyl; hydrocarbonyl; sulphonic or carboxylic acid; R2, R4 represent a hydrogen, a C1-C8 alkyl or alkenyl; —OR?; two groups chosen from R1, R2, R3, R4, R5 and borne by adjacent carbon atoms may form, together with said carbon atoms, a ring or a heterocycle which is optionally substituted, and which is optionally interrupted with one or more carbonyl groups; at least one of the radicals R1, R3, R5 representing a hydrogen; at least one of the radicals R2 or R4 denoting a group —OR? with R? representing a C1-C8 alkyl or alkenyl, it being possible for this radical to form, with the carbon atom bearing itType: GrantFiled: June 25, 2014Date of Patent: June 12, 2018Assignee: L'OREALInventors: Alain Lagrange, Marie Mignon
-
Patent number: 9993412Abstract: The present invention relates to a method for coloring keratin fibers, comprising: —a first step of applying to the fibers a dyeing composition (a) comprising one or more dyes chosen from chromene dyes and chroman dyes, and one or more liquid organic compounds having a Hansen so lubility parameter ?H of less than or equal to 16 Mpa1/2, then —a second step of applying to the fibers an oxidizing composition (b) comprising one or more oxidizing agents and one or more alkaline agents, one or more metal salts and/or metal oxides being present in at least one of the compositions (a) and (b), and/or being applied during an additional step by means of a composition (c). The invention likewise relates to a kit suitable for implementing this method.Type: GrantFiled: December 27, 2013Date of Patent: June 12, 2018Assignee: L'OREALInventors: Boris Lalleman, Alain Lagrange, Françoise Albouy
-
Patent number: 9993413Abstract: Disclosed are compositions for dyeing keratin fibers comprising at least one direct dye and/or an oxidative dye and optionally an activator, and also comprising a compound formed by esterification of phosphoric acid with isooctanol (2-ethylhexanol) and ethoxylated tridecylic alcohol.Type: GrantFiled: February 23, 2017Date of Patent: June 12, 2018Assignee: BEAUTY & BUSINESS S.P.A.Inventors: Antonio Consoli, Katiuscia Grevalcuore, Emanuela Facchetti
-
Patent number: 9993414Abstract: The present invention relates to oral care compositions and methods of inhibiting microbial biofilm formation and/or degrading a microbial biofilm. Disclosed herein are oral care compositions comprising an Amadori compound having a glucose moiety and an amino acid moiety. The Amadori compound has use for inhibiting oral microbial biofilm formation and/or degrading an oral microbial biofilm in the oral cavity of a mammalian subject.Type: GrantFiled: December 17, 2012Date of Patent: June 12, 2018Assignee: Colgate-Palmolive CompanyInventors: Zhigang Hao, Ying Yang, Zhiqiang Liu, Katherine Hu, Guofeng Xu, Paul Joseph Vincenti
-
Patent number: 9993415Abstract: A hair treatment agent in which penetrability of a modified peptide into the internal structure of the hair can be enhanced even under the conditions of acidic pH, and a method for causing a modified peptide to penetrate into the hair, are provided. Disclosed is a hair treatment agent at a pH of from 3.5 to 5.Type: GrantFiled: August 26, 2016Date of Patent: June 12, 2018Assignee: MILBON CO., LTD.Inventors: Yohei Matsumoto, Atsushi Yamada, Naoto Matsumoto
-
Patent number: 9993416Abstract: Disclosed are a mixture of modified polysaccharides and the process of making the modified polysaccharides. Embodiments disclose processing and applying a preparation of the mixture of modified polysaccharides in combination with other bioactive ingredients in aloe, such as amino acids onto the inside surface of a polymer elastomeric flexible article, for example a glove, to enhance the water holding capacity and to regulate pH of the user's skin through effective epidermal penetration.Type: GrantFiled: April 24, 2017Date of Patent: June 12, 2018Assignee: SHEN WEI (USA) INC.Inventors: Belle L. Chou, Sisitha Sudarshana, Athawuda Arachchige Ranthi Manahari Dias
-
Patent number: 9993417Abstract: The present invention relates to a combination comprising a hyaluronic acid or a salt thereof and a sulphated polysaccharide of which the molecular weight is between 5 and 25 kDa, which is of use in particular for combating the signs of skin ageing or for treating and healing skin wounds.Type: GrantFiled: April 30, 2015Date of Patent: June 12, 2018Assignee: PIERRE FABRE DERMO-COSMETIQUEInventors: Stéphane Poigny, Hélène Hernandez-Pigeon, Jean-Hilaire Saurat, Gürkan Kaya
-
Patent number: 9993418Abstract: Consumer product compositions providing enhanced hydrophobic benefit agent deposition. The benefit agent is provided as a benefit agent/deposition aid emulsion, where the benefit agent is physically adsorbed to the deposition aid before the emulsion is added to the balance of ingredients.Type: GrantFiled: July 29, 2014Date of Patent: June 12, 2018Assignee: The Procter & Gamble CompanyInventors: Yonas Gizaw, Steven Daryl Smith, Roy Jerome Harrington
-
Patent number: 9993419Abstract: A method of treating the hair including providing a concentrated hair care composition in an aerosol foam dispenser. The concentrated hair care composition includes one or more silicones, perfume, and less than 10% high melting point fatty compounds. The method also includes dispensing the concentrated hair care composition from the aerosol foam dispenser as a dosage of foam; applying the foam to the hair; and rinsing the foam from the hair. The foam has a density of from about 0.025 g/cm3 to about 0.40 g/cm3 when dispensed from the aerosol foam dispenser.Type: GrantFiled: June 15, 2015Date of Patent: June 12, 2018Assignee: The Procter & Gamble CompanyInventors: Robert Wayne Glenn, Jr., Kathleen Mary Kaufman, Dariush Hosseinpour
-
Patent number: 9993420Abstract: A method of treating the hair including providing a pre-aerated concentrated hair care composition. The pre-aerated concentrated hair care composition includes one or more silicones, perfume, and from about 2% to about 10% high melting point fatty compounds. The method also includes applying the pre-aerated concentrated hair care composition the hair; and rinsing the pre-aerated concentrated hair care composition from the hair. The pre-aerated concentrated hair care composition has a density of from about 0.15 g/cm3 to about 0.75 g/cm3 when dispensed from the aerosol foam dispenser.Type: GrantFiled: June 15, 2015Date of Patent: June 12, 2018Assignee: The Procter & Gamble CompanyInventors: Robert Wayne Glenn, Jr., Kathleen Mary Kaufman, Dariush Hosseinpour, Todd Ryan Thompson
-
Patent number: 9993421Abstract: A method of treating a medical condition resulting from a tattoo has the steps of cleaning at least one surface of the tattoo; preparing a plurality of needles to administer a formulation of a solution containing aloe, less than about 30% salt, carboxymethylcellulose and distilled water; covering the surface of the tattoo surrounding area with injections of the solution until the selected area has a different appearance; spreading the solution on the surface of the tattoo to provide a coating, and permitting the solution to dry. Preferably the salt is Himalayan salt.Type: GrantFiled: November 18, 2016Date of Patent: June 12, 2018Assignee: DYNAMO, LLCInventors: David A. McPherson, James B. Severson, Jr., Samir Haggar
-
Patent number: 9993422Abstract: The present disclosure provides pharmaceutical compositions and processes for making solid dosage form pharmaceutical compositions that provide immediate release of active ingredients and have abuse deterrent properties. The pharmaceutical compositions provided herein comprise at least one pharmaceutically active ingredient, at least one low molecular weight hydrophilic polymer, at least one high molecular weight hydrophilic polymer, and an effervescent system.Type: GrantFiled: April 18, 2013Date of Patent: June 12, 2018Assignee: SpecGX LLCInventors: Siva N. Raman, Jae Han Park, Thomas A. Diezi, Clifford J. Herman, Sunil K. Battu, Eric A. Burge
-
Patent number: 9993423Abstract: The present invention provides a microneedle array which holds a drug only in the microneedle portions, and a method of manufacturing the same. The microneedle array 2A which holds the drug only on the tips of the microneedles can be manufactured by the microneedle deposition method, i.e. a) the microneedle array 2 is prepared using an water-soluble polymer as a base material; b) a drug solution 1 to be applied to the tips of the microneedle array 2 is prepared; and c) the tips of the microneedle array 2 are contacted with the drug solution 1 for a short time. When the drug solution 1 is a water solution, the biodegradable polymer is of water-soluble, and in addition to the drug, the biodegradable polymer is dissolved in the solution at high concentration, the applied drug is integrated with the microneedle so that only the drug does not fall away during insertion.Type: GrantFiled: October 20, 2011Date of Patent: June 12, 2018Assignee: COSMED PHARMACEUTICAL CO., LTD.Inventors: Ying-shu Quan, Fumio Kamiyama
-
Patent number: 9993424Abstract: The present invention relates to a process for the preparation of an intravaginal matrix drug delivery device. The process comprises the steps of combining at least one therapeutic agent in a therapeutically effective amount with at least one biocompatible elastomeric polymer to form a mix; curing said mix in a mold having a shape of said intravaginal drug delivery device, to form a polymer matrix; and maturing said polymer matrix to form the intravaginal drug delivery device. The maturing step alters the release rate characteristics of a device prepared in accordance with the process of the invention.Type: GrantFiled: March 27, 2003Date of Patent: June 12, 2018Assignee: Allergan Pharmaceuticals International LimitedInventors: Brendan Muldoon, Colin Lorimer, Claire Gilligan
-
Patent number: 9993425Abstract: What is described is a pharmaceutical formulation for intranasal delivery of insulin to a patient, comprising an aqueous mixture of human insulin, a solubilizing agent, a surface active agent, and a thickening agent, wherein said formulation provides a ultra-rapid acting profile to regular human insulin.Type: GrantFiled: December 7, 2011Date of Patent: June 12, 2018Assignee: Marina Biotech, Inc.Inventors: Henry R. Costantino, Annemarie Stoudt Cohen, Anthony P. Sileno
-
Patent number: 9993426Abstract: A pharmaceutical composition comprising bisacodyl [4,4?-(pyridine-2-ylmethylene)bis(4,1-phenylene) diacetate], a solvent, a buffer, and a polymer, methods and apparatus for delivery to a patient.Type: GrantFiled: September 7, 2016Date of Patent: June 12, 2018Assignee: C. B. Fleet Company, Inc.Inventors: Nelson P. Ayala, Ping Qiu, Debanjan Das, Dave Zimmerman
-
Patent number: 9993427Abstract: The present invention relates to a liposomal formulation containing a therapeutic agent and a process for producing the formulation. The liposomal formulation comprises particular characteristics that enhance uniformity and stability of the formulation. The manufacturing process is a novel process that produces a liposomal formulation of a uniform size with many desirable properties that may be independently controlled. Further, the invention relates to a liposome formulation made in accordance with the manufacturing process.Type: GrantFiled: March 14, 2013Date of Patent: June 12, 2018Assignee: BIOrest Ltd.Inventors: Yoram Richter, Yehuda Zelig, Omar Elmalak, Dror Eyal
-
Patent number: 9993428Abstract: An instantly floating gastroretentive drug formulation comprising at least one functionalized natural and/or synthetic calcium carbonate-comprising mineral and at least one pharmaceutically active ingredient and at least one formulating aid wherein said functionalized natural or synthetic calcium carbonate is a reaction product of natural or synthetic calcium carbonate with carbon dioxide and one or more acids, wherein the carbon dioxide is formed in situ by the acid treatment and/or is supplied from an external source.Type: GrantFiled: October 10, 2013Date of Patent: June 12, 2018Assignee: Omya International AGInventors: Daniel E. Gerard, Joachim Schoelkopf, Patrick A. C. Gane, Veronika Anna Eberle, Rainer Alles, Maxim Puchkov, Jörg Huwyler
-
Patent number: 9993429Abstract: Provided herein are methods of treating a peripheral nerve injury in a subject. The methods include administering to the subject at or near the site of the peripheral nerve injury an effective amount of a composition comprising an agent that promotes remyelination of the peripheral nerve. Also provided are methods of determining whether a peripheral nerve injury has a capacity for recovery. The methods include selecting a subject with a peripheral nerve injury, administering to the subject a first dose of a composition comprising and agent that promote remyelination and detecting after the first dose one or more characteristics of peripheral nerve recovery, the presence of one or more characteristics of peripheral nerve recovery indicating a peripheral nerve injury has a capacity for recovery and the absence of characteristics of peripheral nerve recovery indicating a peripheral nerve injury without a capacity for recovery.Type: GrantFiled: March 13, 2014Date of Patent: June 12, 2018Assignee: University of RochesterInventors: John Elfar, Kuang-Ching Tseng, Mark Noble
-
Patent number: 9993430Abstract: The present invention relates to solid compositions comprising a GLP-1 peptide and a delivery agent, such as SNAC, as well as uses thereof.Type: GrantFiled: June 19, 2013Date of Patent: June 12, 2018Assignee: Novo Nordisk A/SInventors: Simon Bjerregaard Jensen, Per Sauerberg, Flemming S. Nielsen, Betty L. Pedersen, Erik Skibsted
-
Patent number: 9993431Abstract: The invention relates to the use of an oral dosage form based on microgranules and/or microtablets to reduce the abusive use of at least one active principle contained therein. The aim of the invention is to prevent the diversion of an oral dosage form based on microgranules and/or microtablets containing at least one active principle capable of causing a dependency, a gelling agent, and a gelling activator. The gelling agent and the activator are only brought into contact with each other in the event of diversion by crushing. Said judiciously selected pair of excipients confers a viscosity to the formulation, such that said formulation cannot be administered by injection or does not release the active principle rapidly by forming a gel when it comes into contact with the mucous membrane if nasally administered.Type: GrantFiled: June 7, 2011Date of Patent: June 12, 2018Assignee: EthypharmInventor: Vincent Billoet
-
Patent number: 9993432Abstract: The present invention relates to a pharmaceutical dosage form comprising an active ingredient combination of nifedipine or nisoldipine and at least one angiotensin II antagonist and/or at least one diuretic, characterized in that nifedipine or nisoldipine is released in the body in a controlled (modified) manner and the angiotensin II antagonist and/or the diuretic is released rapidly (immediate release (IR)), and also to processes for their preparation, to their use as medicaments and to their use for the prophylaxis, secondary prophylaxis or treatment of disorders.Type: GrantFiled: November 19, 2009Date of Patent: June 12, 2018Assignee: BAYER INTELLECTUAL PROPERTY GMBHInventors: Alexander Kuhl, Erich Brendel, Frank Bröcker, Adrian Funke, Andreas Ohm, Dennis Kvesic, Thomas Volkmer
-
Patent number: 9993433Abstract: The present invention relates to prolonged release pharmaceutical dosage forms, the manufacture thereof as well as their use for administration to human beings.Type: GrantFiled: May 10, 2011Date of Patent: June 12, 2018Assignee: Euro-Celtique S.A.Inventors: Geoffrey Gerard Hayes, Hassan Mohammad, Harjit Tamber, Malcolm Walden
-
Patent number: 9993434Abstract: Highly compactable granulations and methods for preparing highly compactable granulations are disclosed. More particularly, highly compactable calcium carbonate granulations are disclosed. The granulations comprise powdered materials such as calcium carbonate that have small median particle sizes. The disclosed granulations are useful in pharmaceutical and nutraceutical tableting and provide smaller tablet sizes upon compression than previously available.Type: GrantFiled: May 9, 2016Date of Patent: June 12, 2018Inventors: Kevin W. Lang, James W. Dibble, Raya Levin, Gregory B. Murphy
-
Patent number: 9993435Abstract: A delayed release coating comprising a mixture of a first material selected from starch; amylose; amylopectin; chitosan; chondroitin sulfate; cyclodextrin; dextran; pullulan; carrageenan; scleroglucan; chitin; curdulan and levan, and a second material which has a pH threshold at about pH 5 or above, is used to target release of a drug from a core to the intestine, particularly the colon.Type: GrantFiled: April 1, 2015Date of Patent: June 12, 2018Assignee: UNIVERSITY COLLEGE LONDONInventors: Abdul Waseh Basit, Valentine Chidi Ibekwe
-
Patent number: 9993436Abstract: Using porous hollow fiber membranes, systems/methods for continuously synthesizing polymer-coated particles by anti-solvent crystallization are provided. The disclosed systems/methods provide for synthesis of polymer-coated drug particles/crystals from solutions of the polymer and the drug particles in suspension by exposing the solution to an anti-solvent through a porous hollow fiber device. A feed solution of a coating polymer with suspended drug particles can be exposed to an anti-solvent through hollow fiber pores, thereby causing the polymer to precipitate on and coat the drug particles. In addition, a feed solution of a coating polymer with drug in solution can be exposed to an anti-solvent through hollow fiber pores, thereby causing the drug to crystallize from the solution and the polymer to precipitate/coat the drug. Results indicate that a uniformly coated, free-flowing product may be developed in this advantageous porous hollow fiber anti-solvent crystallization method.Type: GrantFiled: December 14, 2015Date of Patent: June 12, 2018Assignee: New Jersey Institute of TechnologyInventors: Kamalesh Sirkar, Robert Pfeffer, Dengyue Chen, Dhananjay Singh
-
Patent number: 9993437Abstract: A submicron structure includes a silica body defining a plurality of pores that are suitable to receive molecules therein, the silica body further defining an outer surface between pore openings of the plurality of pores; and a plurality of anionic molecules attached to the outer surface of the silica body. The anionic molecules provide hydrophilicity to the submicron structure and are suitable to provide repulsion between other similar submicron structures, and the submicron structure has a maximum dimension less than one micron.Type: GrantFiled: December 8, 2008Date of Patent: June 12, 2018Assignee: The Regents of the University of CaliforniaInventors: Monty Liong, Jie Lu, Fuyuhiko Tamanoi, Jeffrey I. Zink, Andre Nel
-
Patent number: 9993438Abstract: This invention relates to a drug delivery system for administration of poorly water soluble pharmaceutically active substance, a pharmaceutical composition comprising such a drug delivery system, and a method for the preparation of such a drug delivery system. The invention also relates to a method for controlling the particle size and/or particle shape and/or particle size distribution in such a drug delivery system, and to a method for increasing the drug loading capacity of the particles. Furthermore the invention also relates to the use of such a drug delivery system for the preparation of a medicament for the treatment of cancer.Type: GrantFiled: February 27, 2015Date of Patent: June 12, 2018Assignee: Ardenia Investments, Ltd.Inventors: Julian Aleksov, Igor Lokot
-
Patent number: 9993439Abstract: The present disclosure relates generally to a mucoadhesive nanoparticle delivery system. The nanoparticles are formed from amphiphilic macromolecules conjugated to a mucosal targeting moiety in such a manner that the surface of the nanoparticle is coated with the targeting moiety. The surface density of the targeting moiety can be tuned for adjustable targeting of the nanoparticles to a mucosal site without substantially compromising the stability of the particles. The particles were found to have high loading efficiency and sustained release properties at the mucosal site. The present disclosure also relates to polymers and macromolecules useful in the preparation of the mucoadhesive nanoparticles, as well as compositions, methods, commercial packages, kits and uses related thereto.Type: GrantFiled: June 20, 2013Date of Patent: June 12, 2018Assignee: UNIVERSITY OF WATERLOOInventors: Frank X. Gu, Lyndon William James Jones, Shengyan (Sandy) Liu
-
Patent number: 9993440Abstract: The invention provides methods of making and using compositions comprising a polymer shell designed to deliver polypeptides to selected environments. In embodiments of the invention, different environmental conditions are harnessed to allow the selective degradation of the polymer shell and the consequential release of one or polypeptides encapsulated therein. In illustrative embodiments, polymer components of the shell are interconnected by peptide-containing crosslinker moieties, linkages which maintain the integrity of the polymer shell under certain environmental conditions, but can also be cleaved when combined with a selected protease.Type: GrantFiled: September 4, 2012Date of Patent: June 12, 2018Assignee: The Regents of the University of CaliforniaInventors: Yunfeng Lu, Tatiana Segura, Suwei Zhu, Jing Wen
-
Patent number: 9993441Abstract: A biocompatible polymeric controlled release matrix barrier structure for delivery of one or more bioactive agents from an implantable medical device is described. In an embodiment, a biocompatible polymeric controlled release matrix barrier structure is included. The biocompatible polymeric controlled release matrix can include a body structure formed of a compliant material comprising one or more compliant biocompatible polymers and one or more bioactive agents. The body structure can define a central aperture through which a subcutaneous element of an implantable medical device passes. Other embodiments are included herein.Type: GrantFiled: March 26, 2015Date of Patent: June 12, 2018Assignee: Surmodics, Inc.Inventors: Joseph Schmidt McGonigle, Aleksey V. Kurdyumov, Jeffrey J. Missling, Nathan A. Lockwood, Kevin W. Burton, Beth A. Petersen
-
Patent number: 9993442Abstract: This invention concerns a method for treatment or prevention of lower urinary tract symptoms with or without pelvic pain in an individual, said method comprising administering to the individual an effective amount of a selective estrogen receptor modulator, or an isomer, isomer mixture or a pharmaceutically acceptable salt thereof.Type: GrantFiled: August 21, 2015Date of Patent: June 12, 2018Assignee: HORMOS MEDICAL LTD.Inventors: Risto Santti, Tomi Streng
-
Patent number: 9993443Abstract: This invention is directed in part to novel doses, dosage formulations, and routes of administration of such doses and dose formulations, said dose and dose formulations containing one or more copper chelators, for example, one or more trientine active agents, including trientine analogs, trientine salts, trientine prodrugs, and trientine derivatives, useful in the treatment of diseases, disorders and conditions, including in indications where copper may play a role.Type: GrantFiled: July 22, 2016Date of Patent: June 12, 2018Assignee: PhilEra New Zealand LimitedInventor: Garth James Smith Cooper
-
Patent number: 9993444Abstract: The chronic use of p-adrenergic inverse agonists such as nadolol, carvedilol, and ICI-118,551 provides an improved method for the treatment of mucus hypersecretion in subjects with such mucus hypersecretion. One aspect of a method according to the present invention is a method of preventing or controlling mucus hypersecretion in the respiratory tract comprising administering a therapeutically effective quantity of a p-adrenergic inverse agonist to a subject with mucus hypersecretion or at risk of mucus hypersecretion. The invention further encompasses pharmaceutical compositions comprising the p-adrenergic inverse agonist and the additional compound.Type: GrantFiled: January 9, 2012Date of Patent: June 12, 2018Assignee: INVION, INC.Inventors: Richard A. Bond, Mitchell Glass
-
Patent number: 9993445Abstract: Disclosed herein is an oral pharmaceutical composition in the form of an aqueous solution of atomoxetine as an active ingredient. The aqueous solution of atomoxetine comprises a taste-masked liquid carrier comprising peppermint, orange flavor and a viscosity agent. The combined flavors successfully masked atomoxetine hydrochloride's bitter smell and/or taste which makes it a novel palatable pharmaceutical composition. The viscosity agent improves the oral pharmaceutical composition's consistency and provides a smooth texture which makes it easy to swallow. More specifically, the oral pharmaceutical composition comprises effective amounts of: (a) atomoxetine or the pharmaceutically acceptable salts thereof; and (b) a taste-masked liquid carrier. Also provided is a method for making the aqueous solution of atomoxetine. The present disclosure also provides methods of using oral pharmaceutical composition for the treatment of a subject having a disorder treatable by the administration of atomoxetine.Type: GrantFiled: November 29, 2017Date of Patent: June 12, 2018Assignee: TAHO PHARMACEUTICALS LTD.Inventors: Chin Chung Lin, Chien-Chiao Wang, Catherine Lee
-
Patent number: 9993446Abstract: A biguanide derivative compound with N1-N5 substitution, which is represented by Formula 1, or a pharmaceutically acceptable salt thereof a method of preparing the same, and a pharmaceutical composition containing the same as an active ingredient are provided. The biguanide derivative may exhibit excellent effect on activation of AMPK? and inhibition of cancer cell proliferation in a low dose, compared to conventional drugs, and thus, may be useful to treat diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, fatty liver, coronary artery disease, osteoporosis, polycystic ovarian syndrome, metabolic syndrome, cancer, etc.Type: GrantFiled: July 11, 2016Date of Patent: June 12, 2018Assignee: Immunomet Therapeutics Inc.Inventors: Sung Wuk Kim, Sung Soo Jun, Chang Hee Min, Young Woong Kim, Min Seok Kang, Byung Kyu Oh, Se Hwan Park, Yong Eun Kim, Duck Kim, Ji Sun Lee, Ju Hoon Oh
-
Patent number: 9993447Abstract: Formulations of hydrosoluble stable organic salts including, but not limited to, agmatine orotate, agmatine di-hydrochloride, agmatine phosphate, buffered agmatine or spray dried buffered agmatine base, whether alone or in combination with one another, are provided, as well as methods for making same. These agmatine salts may have improved solubility in aqueous and organic media and may have increased absorbability and/or tissue bioavailability in humans and animals when compared to agmatine sulfate. These formulations may be administered as a means for improving athletic performance, training resistance and/or cognitive function. These formulations also may increase cellular uptake of agmatine in an animal or human.Type: GrantFiled: September 13, 2016Date of Patent: June 12, 2018Assignee: JW Nutritional, LLCInventors: Dragos Alevizache, Jesse Windrix
-
Patent number: 9993448Abstract: A method of delivering a daily dose of hydroxycitric acid in the form of a salt as a single bolus that is as effective or more so than the same amount of active delivered via two or three administrations (b.i.d. or t.i.d.) using current delivery modalities. The method reduces the rate of occurrence of common adverse events with hydroxycitric acid salts, and reduces the occurrence of reverse effects on diets high in fat and/or alcohol. The method improves the uptake of the active compound thereby reducing the dose required.Type: GrantFiled: September 11, 2017Date of Patent: June 12, 2018Assignee: GLYKON TECHNOLOGIES GROUP, LLCInventors: Dallas L. Clouatre, Daniel E. Clouatre, Brad J. Douglass
-
Patent number: 9993449Abstract: Cyclopentene carboxylic acid-related compounds as GABA-AT inhibitors for treatment of various addictions, disorders and disease states.Type: GrantFiled: May 4, 2017Date of Patent: June 12, 2018Assignee: NORTHWESTERN UNIVERSITYInventors: Richard B. Silverman, Kenji Takaya, Hoang V. Le, Jose I. Juncosa
-
Patent number: 9993450Abstract: Compositions of L-4-chlorokynurenine are provided, as are methods for the treatment of neurological dysfunction.Type: GrantFiled: January 22, 2014Date of Patent: June 12, 2018Assignee: VISTAGEN THERAPEUTICS, INC.Inventors: H. Ralph Snodgrass, Allen E. Cato, Jack S. Hicklin
-
Patent number: 9993451Abstract: Disclosed herein are compositions that include for example the arginine salt of carbidopa, and methods for treating neurological or movement diseases or disorders such as restless leg syndrome, Parkinson's disease, secondary parkinsonism, Huntington's disease, Parkinson's like syndrome, PSP, MSA, ALS, Shy-Drager syndrome and conditions resulting from brain injury including carbon monoxide or manganese intoxication, using substantially continuous administration of carbidopa or salt thereof together with administration of levodopa.Type: GrantFiled: July 1, 2015Date of Patent: June 12, 2018Assignee: NeuroDerm, LTD.Inventors: Oron Yacoby-Zeevi, Mara Nemas
-
Patent number: 9993452Abstract: The present invention is directed to novel anti-inflammatory immunomodulators including creatinine or a creatinine salt, for example, creatinine hydrochloride. The present invention is also directed to methods for treating inflammation and inducing an immunomodulatory response. In particular, the anti-inflammatory immunomodulators are useful for treating an inflammatory condition or an autoimmune disease.Type: GrantFiled: December 7, 2015Date of Patent: June 12, 2018Assignees: Vireo Systems, Inc., Creighton UniversityInventors: Thomas McDonald, Kristen Drescher
-
Patent number: 9993453Abstract: Compositions of L-4-chlorokynurenine are provided, as are methods for the treatment of neurological dysfunction.Type: GrantFiled: February 8, 2016Date of Patent: June 12, 2018Assignee: VISTAGEN THERAPEUTICS, INC.Inventors: H. Ralph Snodgrass, Allen E. Cato, Jack S. Hicklin